Dostarlimab with Cisplatin, Etoposide, and Radiotherapy for Small Cell Neuroendocrine Cervical Carcinoma in Women Aged 20 to 70

What this Trial Is About

Researchers are evaluating the addition of dostarlimab to chemoradiation with etoposide, cisplatin, and radiotherapy for treating small cell neuroendocrine cervical carcinoma SCNECC. This phase 2 trial aims to improve progression-free survival compared to historical treatments of chemoradiation alone. The study focuses on female patients with untreated SCNECC, exploring whether the combined approach improves outcomes. Participants will receive dostarlimab at a dose of 500 mg every 3 weeks during the chemoimmunotherapy phase. This treatment is combined with cisplatin, etoposide, and radiotherapy given in a sandwich sequence. The dosing schedule is based on existing data supporting these doses for adults across tumor types. The study treatment will be administered over a planned period with careful monitoring. During the study, participants will undergo evaluations including performance status assessments and tumor biopsies. Researchers will monitor progression-free survival over 2 years, defined from the start of chemotherapy with dostarlimab to disease progression per RECIST 1.1 criteria. Safety and treatment effects will be tracked, with participants followed closely throughout the treatment and observation periods, which may extend up to several years.

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma